Control Bionics Ltd. (ASX:CBL) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares Announced: about A$9.5M · A$0.075 a share · Bell Potter Securities Limited +1 Dealers: Bell Potter Securities Limited (co-lead), Unified Capital Partners Pty Ltd (co-lead) Buyers: Stephen Rix (2,040,000 shares, subject to shareholder approval); Jeremy Steele (1,160,000 shares, subject to shareholder approval); Nicholas Opie (400,000 shares, subject to shareholder approval); Robert Heard (333,333 shares, subject to shareholder approval); Damian Lismore (320,000 shares, subject to shareholder approval) Insiders: Tranche 2 includes approximately 4.3 million shares (4,253,333) to directors, subject to shareholder approval Use of proceeds: Commercialisation initiatives and working capital | Jun 25, 2026 | US$6.57M |
| Share purchase plan of new shares Announced: up to A$500,000 · A$0.075 a share Use of proceeds: Commercial expansion, platform and medtech development, strategic initiatives, working capital and offer costs | Jun 25, 2026 | US$345,572 |
| Private placement of new fully paid ordinary shares Announced: A$3.25M · A$0.065 a share Buyers: Reitham Equity GmbH (anchored the placement) Use of proceeds: Working capital to accelerate commercialisation of core assistive technology products and emerging neurotechnology markets | Dec 1, 2025 | US$2.13M |